公开(公告)号：US20130210782A1

公开(公告)日：2013-08-15

申请号：US13840825

申请日：2013-03-15

Applicant: DSM IP ASSETS B.V.

Inventor： Neil Robert Buck ,  Wouter Claerhout ,  Bruno H. Leuenberger ,  Elisabeth Stoecklin ,  Kai Urban ,  Swen Wolfram

IPC: A61K31/593

CPC classification number: A61K31/593 ,  A23L33/155 ,  A23V2002/00 ,  A61K31/59 ,  A61K2300/00 ,  A23V2200/326 ,  A23V2250/71

Abstract: We disclose treating hyperglycemia in a human with 25-hydroxyyitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.

Abstract translation: 我们公开了用25-羟基维生素D3（calcifediol）处理人的高血糖症。 血糖降低到比基线更接近正常水平。 维生素D3（胆钙化醇）可以任选与25-羟基维生素D3一起使用。 还公开了药物组合物的形式和剂量，以及制备药物的方法。

公开(公告)号：US09241938B2

公开(公告)日：2016-01-26

申请号：US14548437

申请日：2014-11-20

Applicant: DSM IP ASSETS B.V.

Inventor： Angelika Friedel ,  Karin Kuratli ,  Christof Wehrli ,  Karin Wertz ,  Swen Wolfram ,  Ying Wang-Schmidt

IPC: A01N65/00 ,  A61K31/455 ,  A61K36/00 ,  A23L1/30 ,  A23L1/302 ,  A61K31/46 ,  A23L1/29 ,  A61K36/74 ,  A61K45/06

CPC classification number: A61K31/455 ,  A23L33/105 ,  A23L33/15 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/46 ,  A61K36/00 ,  A61K36/74 ,  A61K45/06 ,  A23V2200/316 ,  A23V2250/7046 ,  A23V2250/21

Abstract: This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity.

Abstract translation: 本发明涉及痤疮化合物在活动期间增加肌肉重量或在不活动期间抑制肌肉损失的用途。

公开(公告)号：US10357501B2

公开(公告)日：2019-07-23

申请号：US15393160

申请日：2016-12-28

Applicant: DSM IP ASSETS B.V.

Inventor： Stephanie Krammer-Lukas ,  Elisabeth Stoecklin ,  Joseph Schwager ,  Swen Wolfram

IPC: A61K31/59 ,  A61K47/00 ,  A61K31/593 ,  A23L33/155 ,  A61K9/00 ,  A61K9/48

Abstract: Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.